Anti-V(beta)3 T cell receptor (TcR) [JOVI.3]
Invented by Dr Mike Owen from Independent Pharmaceutical And Biotech Consultant
Invented at Cancer Research UK London Research Institute: Lincoln's Inn Fields
- Datasheet
- References (8)
- Inventor Info
Info
| Catalogue Number | 152627 |
| Applications | FACS IHC IP Fn |
| Antigen/Gene or Protein Targets | V(beta)3 T cell receptor (TcR) |
| Reactivity | Human |
| Relevance |
Monoclonal antibody used in the study of T cell diseases, and as a CAR therapy in T cell lymphoma/leukaemia. Background and Research Application The T cell receptor is heterodimer of alpha/beta or gamma/delta chains, expressed on all mature T cells. TCR’s recognise antigen peptides bound to MHC molecules, providing the basis of antigen specific response by T cells. JOVI.3 can be used for studies of T cell mediated diseases, including autoimmunity and allergy. The antibody recognises any human T cell receptor that has the vß3 region, staining 50-75% % of peripheral blood T cells and T cell lines. |
| Host | Mouse |
| Immunogen | Thymus, spleen and mesenteric lymph nodes isolated from a mouse transgenic for human Vb3 TcR. |
| Immunogen UniProt ID | P09693 |
| Positive Control | CD3 positive PBMCs |
| Subclass | IgG2a |
| Myeloma Used | P3/NS1/1-Ag4.1 |
| Recommended Growing Conditions | DMEM + 5% FCS |
| Notes |
Production Details Purified using multi-step affinity chromatography with protein A. Storage Conditions Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles. Points of Interest Antibody JOVI-3 is mitogenic for T cells expressing TCR V beta 3. V beta 3 sequence was chosen because of its reported elevated usage in the synovial T cells of rheumatoid arthritis patients. This antibody has been combined into a chimeric antigen receptor therapy approach, with the aim to selectively deplete the subset of T cells in T cell lymphomas or leukaemias, whilst leaving the non-reactive T cell subset intact. Concentration 1mg/ml as standard |
| Research Area | Cell Type or Organelle Marker, Immunology |
References: 8 entries
Viguier et al. 2015. J Invest Dermatol. 135(2):418-24. PMID: 25207820.
Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus.
Europe PMC ID: 25207820
San José et al. 1999. J Biol Chem. 274(47):33740-6. PMID: 10559266.
Fn
Receptor engagement transiently diverts the T cell receptor heterodimer from a constitutive degradation pathway.
Europe PMC ID: 10559266
Sahuquillo et al. 1998. J Exp Med. 187(8):1179-92. PMID: 9547330.
IP
T cell receptor (TCR) engagement in apoptosis-defective, but interleukin 2 (IL-2)-producing, T cells results in impaired ZAP70/CD3-zeta association.
Europe PMC ID: 9547330
Viney et al. 1992. Hybridoma. 11(6):701-13. PMID: 1284120.
FACS IHC IP
Generation of monoclonal antibodies against a human T cell receptor beta chain expressed in transgenic mice.
Europe PMC ID: 1284120
Add a reference
References: 8 entries
Viguier et al. 2015. J Invest Dermatol. 135(2):418-24. PMID: 25207820.
Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus.
San José et al. 1999. J Biol Chem. 274(47):33740-6. PMID: 10559266.
Fn
Receptor engagement transiently diverts the T cell receptor heterodimer from a constitutive degradation pathway.
Sahuquillo et al. 1998. J Exp Med. 187(8):1179-92. PMID: 9547330.
IP
T cell receptor (TCR) engagement in apoptosis-defective, but interleukin 2 (IL-2)-producing, T cells results in impaired ZAP70/CD3-zeta association.
Viney et al. 1992. Hybridoma. 11(6):701-13. PMID: 1284120.
FACS IHC IP
Generation of monoclonal antibodies against a human T cell receptor beta chain expressed in transgenic mice.
Add a reference
